anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain samplers which are nice in form and hygienic in use economically, by arranging an integral applicator or an applicator which is one-piece with the paper base in a second position different from a first position on the paper base. SOLUTION: On a portion of a paper base 21, e.g. a lipstick sample 20 is arranged, around which is also arranged an eye shadow sample 30. An applicator 40 is arranged by making use of a part of the paper base. The applicator may take the shape of a brush or a spatula, with its surface flock-finished so that cosmetic materials are easy to be attached. The applicator may also be so processed as to be capable of scooping. The applicator 40 is integral with the base, i.e., a part of the paper base is made as the applicator, or a separately prepared applicator is strippably attached to the base. If the applicator 40 is part of the base, it can be taken out by breaking the dotted line. The paper base, cosmetic samples and the applicator are strippably overlaid by a protective cover 24.
The study will be conducted in 2 stages. In Stage 1 of the study, successive groups of 3 to 6 patients will receive progressively higher PTC299 dose levels; in this stage, treatment will be given in repeated 6-week cycles consisting of 4 weeks of oral PTC299 twice per day followed by a 2-week, no-drug period. During Stage 2, study candidates must be women with natural or induced suppression of ovarian function to post-menopausal levels who are receiving or are candidates for hormonal therapy. These subjects will receive continuous administration of PTC299, 100 mg/dose BID, in repeated 6-week cycles in combination with continuous administration of one of 3 hormonal agents. All planned PTC299 dose levels in all stages are expected to achieve circulating blood levels of PTC299 known to be active in animal models of human cancer. Treatment for each patient can continue as long as the therapy appears to be safely offering tumor control to that patient. Up to 36 evaluable patients will be accrued across both stages.
The invention discloses ear drum membrane regeneration medicine powder which comprises the following raw materials in percentage by weight: 20% of catechu, 10% of resina draconis and 70% of pearl powder. A preparation method of the medicine powder comprises the following steps: weighing according to a recipe, grinding the catechu, the resina draconis and the pearl powder into fine powder respectively, passing a 300-mesh sieve, and mixing to obtain the medicine powder. A treatment method of the medicine powder is as follows: the external auditory canal is washed by 3% hydrogen peroxide and the ground mixed medicine powder is blown to the ears once a day. The medicine powder is a novel ear drum membrane treatment technology successfully researched and developed according to a traditional Chinese medicine principle of eliminating necrotic tissues and promoting granulation. The medicine powder is directly applied to the affected parts, and the healing rate reaches more than 98%. A clinical test proves that the medicine powder has good effects of stasis removal, separation, sterilization, inflammation diminishment, liquefaction, granulation promotion and the like, pus no longer flows in the ears, the membrane is regenerated and healed after tympanic membrane perforation, and the hearing is remarkably improved and completely recovered. According to the medicine powder, the pain is relieved for patients with acute and chronic otitis media and traumatic tympanic membrane perforation; the antibiotic consumption and the harm of antibiotics to a human body are reduced; the medical expenses of states and the patients are saved.
Benign breast disease is frequently encountered in female patients, a significant proportion of who are premenopausal women. Established methods of treatment do not yield significant results. This is not only a social burden but also entails high economic cost. As such the quality of life of these patients is a matter of concern for both the patients and their families and to attending physicians. Reported effects of tamoxifen on benign breast disease in premenopausal non high risk patients are scarce. Moreover published data has not yet revealed association of estrogen receptors in different benign breast lesions.The variability of response and its relation with estrogen receptor status is still a field of active investigation.
The invention discloses a traditional Chinese external medicine for treating anal fissures. The traditional Chinese external medicine for treating the anal fissures is characterized by being composed of active ingredients of, based on the ratio: 74% of unguentum guaiazuleni, 6% of medical camphor, 4% of radix angelicae, 4% of corydalis tuber, 4% of coptis chinensis, 4% of phellodendron amurense, and 4% of panax notoginseng. The Chinese patent drugs are uniformity stirred and mixed into ointment after being porphyrized. When using the ointment, a user only needs to externally apply the ointment on an affected part. The ointment works wonders for the anal fissures, and has an effective rate above 95%. Simultaneously, the ointment has a preventive effect and a therapeutic effect for both external piles and internal piles.
An outpatient ambulatory patient worn apparatus for managing chronic lung disease includes a plurality of sensors configured to be worn by a patient and to measure a plurality of physiological data. The plurality of sensors includes at least an oximeter, a respiratory rate sensor, and at least one activity or motion sensor. A central monitoring unit (CMU) is worn by the patient in an outpatient setting during activities of daily living. The CMU categorizes each recorded measurement of each of the plurality of sensors stored in a set of time stamped primary data by a predominate activity type to generate a set of activity type stamped data, the predominate activity types include rest, exertion, and sleep. A generate report process provides at least one or more reports. An outpatient ambulatory patient worn long-term oxygen therapy (LTOT) apparatus and a method for managing chronic lung disease are also described.
Methods for securely validating a test are provided. In one aspect, the method includes receiving an enrollment request from a user device associated with an individual. The method includes generating a profile associated with the individual and storing the profile on a blockchain network, wherein the profile comprises profile data. The method includes receiving a test result associated with a test of the individual and updating the profile with the test result. The method includes determining whether a facility associated with the test result is an approved certifying facility. The method includes creating, responsive to determining that the facility is one of the approved certifying facilities, a unique code associated with the individual, wherein the unique code comprises an indication of the test result. The method includes transmitting the unique code to the user device associated with the individual. Systems and machine-readable media are also provided.
PROBLEM TO BE SOLVED: To obtain a capsule particle improved in solubility of a coating film, capable of forming a capsule, comprising a specific water-soluble substance in high content in a gelatin in the coating film. SOLUTION: This capsule particle is obtained by blending 100 pts.wt. gelatin with 100-200 pts.wt. of a water-soluble substance having >=25g solubility in 100g water at 25 deg.C. A substance selected from a saccharide, an inorganic salt and a water-soluble alcohol is preferable as the water-soluble substance. Saccharose, sorbitol and glycerol are preferable among them. The shape of a coating film formed by the capsule particle is preferably seamless. The capsule particle preferably contains a liquid composed of a surfactant and/or an oily component as contents. The capsule particle is obtained by extracting and removing water in the capsule particle by using an extracting solution containing a water soluble substance and a hydrophilic organic solvent. The thickness of the coating film is preferably <=0.3mm.
Systems and methods for cancer subject tumor fraction estimation comprise obtaining a first plurality of nucleic acid fragment sequences from the subject's liquid biological sample. The first plurality of sequences represent cell-free nucleic acids in the liquid sample. A second plurality of nucleic acid fragment sequences is obtained from the subject's tumor sample. The second plurality of sequences represent nucleic acid molecules in the tumor. Smoothed noise rates, each determined using nucleic acid fragment sequences from non-cancer samples mapping to a corresponding allele position in a plurality of allele positions, are obtained. Variant allele counts and coverages are determined for the allele positions using the first plurality of sequences. Solid variant allele fractions are determined for the plurality of allele positions using the second plurality of sequences. The subject tumor fraction is calculated using the smoothed noise rates, variant allele counts, coverages, and solid variant allele fractions.
Subjects will receive double blind 15 mg FBE IV danirixin twice daily with open label 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.
Screening period (day 0): normal routine medical sheet and skin care regimen. Intervention days 1, 2, 3, 4, 5: MoliCare Premium Bed Mats and skin care regimen.
All patients were required to sign a consent form prior to undertaking any study-related procedures. Prospective patients were screened to determine if they qualified for the study within 28 days of enrollment. Patients who qualified received TRC105 i.v. over 1 to 4 hours on Day 1, Day 4, Day 8 and Day 15 of the initial 21-day cycle and Day 1, Day 8 and Day 15 of every subsequent 21-day cycle in combination with 1000 mg/m2 capecitabine BID for 14 days of each 21-day cycle. Those who tolerated TRC105 without any infusion reactions were eligible for reduced infusion durations. After 3 cycles of treatment, patients who demonstrated a response of complete response (CR), partial response (PR) or stable disease (SD) were eligible for additional treatment for up to six months (9 total cycles). Upon discussion with TRACON, patients judged by the Principal Investigator to be benefiting from treatment were able to continue treatment on this protocol beyond six months.

Toxicities were graded according to the NCI CTCAE Version 4.0. Patients who exited the study for reasons other than drug-related toxicity prior to completion of the first 21-day cycle were replaced. Intra-patient dose escalation was not allowed.
BACKGROUND: Sleep, or a lack thereof, is strongly related to mood dysregulation. Although considerable research uses symptom scales to examine this relation, few studies use longitudinal, real-time methods focused on pediatric irritability. This study leveraged an ecological momentary assessment (EMA) protocol, assessing bidirectional associations between momentary irritability symptoms and daily sleep duration in a transdiagnostic pediatric sample enriched for irritability.
METHODS: A total of N = 125 youth (Mage = 12.58 years, SD = 2.56 years; 74% male; 68.8% White) completed digital, in vivo surveys three times a day for 7 days. For a subset of youth, their parents also completed the EMA protocol. Trait irritability was measured using youth-, parent-, and clinician-report to test its potential moderating effect on the association between sleep duration and momentary irritability.
RESULTS: Results from multilevel modeling dynamically linked sleep to irritability. Specifically, according to youth- and parent-report, decreased sleep duration was associated with increased morning irritability (bs ≤ -.09, ps < .049). A bidirectional association between parent-reported nightly sleep duration and anger was found-increased evening anger related to decreased nightly sleep duration, and decreased sleep duration related to increased morning anger (bs ≤ -.17, ps < .019). Trait irritability moderated this association, which was stronger for more irritable youth (b = -.03, p < .027).
CONCLUSIONS: This study adds to the literature and suggests sleep-irritability dynamics as a potential treatment target.
PURPOSE:To obtain an antiviral agent, containing a naphtho[1,8-cd]-1,2-dithiol derivative as an active ingredient and having slight toxicity or side effects. CONSTITUTION:This antiviral agent contains a compound of the formula (R<1> to R<6> are each H, a lower alkyl, a lower alkenyl, an aryl, an aralkyl, nitro, cyano, an alkoxycarbonyl, an acyl, etc.) or its salt as an active ingredient. The compound has excellent antiviral actions and is effective against viral diseases represented by respiratory diseases such as upper respiratory infection, lower respiratory infection, bronchitis, bronchiolitis or croup in which a respiratory syncytial (RS) virus participates. The naphtho[1,8-cd]-1,2-dithiol derivative or its salt is formulated as a pharmaceutical preparation by adding an optional and required pharmaceutically permissible additive such as a carrier or an excipient thereto according to a conventional method. The daily dose for an adult is 10-1000mg, preferably 100-500mg.
BACKGROUND AND OBJECTIVES: The prognosis of patients with spontaneous intracerebral hemorrhage (ICH) is often influenced by hematoma volume, a well-established predictor of poor outcome. However, the optimal intraventricular hemorrhage (IVH) volume cutoff for predicting poor outcome remains unknown.
METHODS: We analyzed 313 patients with spontaneous ICH not undergoing evacuation, including 7 cases with external ventricular drainage (EVD). These patients underwent a baseline CT scan, followed by a 24-hour CT scan for measurement of both hematoma and IVH volume. We defined hematoma growth as hematoma growth > 33 % or 6 mL at follow-up CT, and poor outcome as modified Rankin Scale score≥3 at three months. Cutoffs with optimal sensitivity and specificity for predicting poor outcome were identified using receiver operating curves.
RESULTS: The receiver operating characteristic analysis identified 6 mL as the optimal cutoff for predicting poor outcome. IVH volume> 6 mL was observed in 53 (16.9 %) of 313 patients. Patients with IVH volume>6 mL were more likely to be older and had higher NIHSS score and lower GCS score than those without. IVH volume>6 mL (adjusted OR 2.43, 95 % CI 1.13-5.30; P = 0.026) was found to be an independent predictor of poor clinical outcome at three months in multivariable regression analysis.
CONCLUSIONS: Optimal IVH volume cutoff represents a powerful tool for improving the prediction of poor outcome in patients with ICH, particularly in the absence of clot evacuation or common use of EVD. Small amounts of intraventricular blood are not independently associated with poor outcome in patients with intracerebral hemorrhage. The utilization of optimal IVH volume cutoffs may improve the clinical trial design by targeting ICH patients that will obtain maximal benefit from therapies.
BACKGROUND: Long-term information on health-related quality of life (HRQOL) and mental health of non-hospitalized individuals with "post COVID-19 syndrome" (PCS) is scarce. Thus, the objectives of the present study were to compare HRQOL and mental health of individuals with and without PCS in a German sample of non-hospitalized persons after SARS-CoV-2 infection, to characterize the long-term course up to 2 years and to identify predictors for post COVID-19 impairments.
METHODS: Individuals with past SARS-CoV-2 infection were examined at the University Hospital of Augsburg from November 2020 to May 2021 and completed a postal questionnaire between June and November 2022. Participants who self-reported the presence of fatigue, dyspnea on exertion, memory problems or concentration problems were classified as having PCS. HRQOL was assessed using the Veterans RAND 12-Item Health Survey, mental health was measured by the Patient Health Questionnaire and the Fatigue Asessment Scale was used to assess fatigue severity. Multivariable linear regression models with inverse probability weighting were used to determine the association between PCS and health outcomes.
RESULTS: From the 304 participants (58.2% women, median age 52 years), 210 (69.1%) were classified as having PCS in median 26 months after SARS-CoV-2 infection. Persons with PCS showed significantly more often depressive and anxiety disorders. PCS was independently and significantly associated with higher levels of depression, post-traumatic stress and fatigue, as well as poorer physical and mental HRQOL in median 9 months as well as 26 months after SARS-CoV-2 infection. A large number of acute symptoms and a prior diagnosis of depression were independently associated with poor mental health and HRQOL. While post-traumatic stress and mental HRQOL improved from 9 months to 26 months post infection onset, depressiveness, fatigue and physical HRQOL remained stable in both, persons with and without PCS.
CONCLUSIONS: PCS in non-hospitalized persons after SARS-CoV-2 infection is often associated with long-term impairments of mental health and HRQOL outcomes.
Participants will complete the training protocol that, after completion of preliminary basic science experiments, is found to most effectively reduce tilt thresholds AND improve balance in young adults. The potential training stimulus parameters are as follows: (1) roll tilt, pitch tilt, LARP tilt, or RALP tilt motion, (2) stimulus size will be adjusted based upon subject responses using either a 2D/1U, 3D/1U, or 6D/1U staircase, and (3) either auditory, visual, or combined auditory+visual feedback will be provided. The training protocol will be completed first, followed by the placebo intervention.
Subjects with non-inflammatory pericardial effusion who require diagnostic or therapeutic pericardiocentesis. Four ml of pericardial fluid should be collected: 2 ml for biochemical analysis in lithium heparin or serum-gel separator-associated tubes, and 2 ml for cellular analysis in K3 EDTA tubes.
Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
A respiratory system and method comprise a tracker module adaptable to be secured to a variety of inhalers, the tracker module sensing activation of the medication canister of the inhaler for delivery of medication to a user. The tracker module also senses the rate of inhalation air flow of the user when inhaling medication for determination of proper inhaler use. Upstream and downstream sensors provide flow information to determine quality of the inhalation. A flow sensor is an integral part of the tracking module and can be used on multiple inhalers. Other sensors are provided that monitor user presence at the inhaler, user technique in using the inhaler, and the attitude of the inhaler when it was used. Low power devices are used to conserve battery power. A spirometer provides user lung function data.
Health-promoting foods containing as the active ingredient processed products of Umbelliferae Angelica furcijuga and health-promoting foods containing as the active ingredient mixtures of plants belonging to Umbelliferae Angelica and plants belonging to Orchidaceae Calanthe. For example, dried whole plants (leaves, stems, roots, etc.) of plants of Angelica and Calanthe are washed with water and roughly cut with a cutter. 2 kg of the Angelica plant pieces are boiled in 20 l of water, while 1 kg of the Calanthe plant pieces are boiled in 10 l of water.  These mixtures are cooked over a low flame to reduce the volume to about 1/3. After boiling and cooling by allowing to stand to room temperature, these mixtures are filtered and combined. To the obtained mixture, 5 to 15 % of black vinegar is added to regulate the pH value to about 4 to 5. Then an appropriate amount of a sweetener is added thereto. The extract thus obtained has the potent effects of ameliorating diseases (anticancer effect, anti-inflammatory effect, etc.) of Angelica as well as the potent antibacterial effect and anti-inflammatory effect of Calanthe, thereby giving health-promoting foods which have never been obtained so far.
Postoperative Ileus refers to the transient interruption of propulsive motor activity of the gastrointestinal (GI) tract that prevents effective movement of its contents and tolerance of oral intake. Although POI is generally considered to significantly increase hospital stays and inpatient costs after spinal surgery, the incidence, associated risk factors, and effective preventative strategies remain poorly characterized. The proposed etiologies underlying POI are broad and remain incompletely characterized. They include post surgical sympathetic nervous system activation, inflammatory factors, and the effects of analgesics on GI tract motility. Treatment often consists of aggressive bowel regimens, nasogastric tube insertion for decompression, and the application of various laxatives, suppositories, and enemas. The widespread use of these measures is unfortunately not supported by high level evidence. The incidence of POI after spinal fusion is reported to range between 0.6 to 16.7%. This estimated range likely represents a gross underestimate of POI given the retrospective nature of studies undertaken to date. Fineberg and colleagues reported that the risk increases nearly 3-fold following anterior lumbar spinal fusions as compared to posterior surgeries. Furthermore, the only risk factors they identified to be correlated with POI is male gender, = 3 fusion levels, alcohol abuse, anemia, electrolyte abnormalities, and weight loss. Kiely and colleagues found that ileus was associated with the administration of certain intravenous solutions such as lactated ringers and sodium chloride. Interestingly, they found that albumin administration was associated with a reduced incidence of ileus postoperatively. Lee and colleagues evaluated POI following orthopedic surgery and reported an incidence of 2.1%. They found that patients who developed POI were more likely to be older, had higher blood loss during surgery, and also had higher rates of preoperative constipation. This study, however, included all types of orthopedic surgeries (not limited to spinal fusion). Early clinical studies evaluated the effectiveness of MNTX in treating opioid-induced constipation (OIC). Several clinical trials confirmed that MNTX was well tolerated and counteracted the GI effects of opioids, thereby enhancing gut motility without inhibiting their analgesic properties. Only two studies to date have evaluated the potential effectiveness of MNTX in reducing the incidence of POI following GI surgery. Both studies were unfortunately hampered by serious design flaws. Most importantly, neither study included pre-operative administration of MNTX. As such, MNTX remains at this time approved only for chronic OIC based on two double-blind, randomized, placebo-controlled trials conducted in patients with advanced illness wherein MNTX rapidly induced laxation as compared to placebo.